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Abstract
 Aims—Cigarette smoking has been associated with incident heart failure independent of 
coronary artery disease (CAD), but the mechanisms linking smoking to cardiac damage are not 
well understood. This study sought to evaluate the relationship between smoking and N-Terminal 
Pro-Brain Natriuretic Peptide (NT-ProBNP) and high-sensitivity Troponin T (hs-TnT), respective 
biomarkers of myocardial wall stress and injury, in a large community-based cohort.
 Methods and Results—We examined the association between smoking history and NT-
ProBNP and hs-TnT in 9,649 participants free of overt CAD or heart failure from the 
Atherosclerosis Risk in Communities (ARIC) Study who attended Visit 4 (1996–1998), as well as 
the association with change in these biomarkers from Visit 4 to Visit 5 (2011–2013) in 3,151 
participants. At Visit 4, higher cumulative cigarette exposure, assessed by total pack-years, was 
associated with elevated levels of NT-ProBNP (p<0.001) and hs-TnT (p=0.01) among ever 
smokers in multivariable analyses adjusted for potential confounders. After 15 years of follow-up, 
participants who were active smokers at Visit 4 had greater incidence of elevated NT-ProBNP 
(adjusted proportion [95%CI] = 48 [41, 54] vs. 35 [32, 39]%; p=0.006] and hs-TnT [adjusted 
proportion [95%CI] = 32 [26, 38] vs. 23 [20, 26]%; p=0.021) compared to never smokers, 
adjusting for baseline and follow-up covariates.
 Conclusions—In a large community-based cohort free of overt CAD and heart failure, 
cigarette smoking was associated with biomarkers of myocardial wall stress and injury at baseline 
as well as with a continued measurable increase in these biomarkers after 15 years of follow-up.
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 INTRODUCTION
Cigarette smoking is a leading preventable cause of cardiovascular morbidity and mortality 
(1). Epidemiological studies have suggested that active smokers and to a lesser extent former 
smokers are at higher risk for developing heart failure (HF) even after adjusting for coronary 
artery disease (CAD) (2, 3). Animal studies suggested that tobacco smoke may exert direct 
toxic effects on the myocardium (4), while clinical showed associations between smoking 
and alterations in cardiac function in subjects without overt cardiovascular disease (5, 6). 
Altogether, these observations support the notion that tobacco use might directly affect 
myocardial integrity. However, the potential mechanisms linking smoking to cardiac damage 
remain unclear.
N-Terminal Pro-Brain Natriuretic Peptide (NT-ProBNP) and high-sensitivity Troponin T 
(hs-TnT) are recognized as diagnostic and prognostic circulating biomarkers of cardiac 
dysfunction (7, 8). NT-ProBNP increases in response to hemodynamic stress, which occurs 
when myocardial chambers are dilated, hypertrophied, and/or subject to increased wall 
tension, while hs-TnT increases as a consequence of cardiomyocyte injury and/or necrosis 
(7). Cross-sectional data from community-based cohorts have provided conflicting results 
regarding the associations between smoking history and NT-ProBNP (9, 10, 11) or hs-TnT 
(10, 12, 13, 14) levels. Additionally, greater upward trajectories of NT-ProBNP and hs-TnT 
levels over several years are associated with a heightened risk of developing cardiac 
dysfunction compared to smaller variations over time (15). Therefore, consideration not only 
of baseline levels but also of temporal changes in NT-ProBNP and hs-TnT may be useful 
approaches to assess potential mechanisms involved in myocardial damage. However, the 
impact of smoking status on the long-term changes of these biomarkers is uncertain.
We analyzed the association between smoking and NT-ProBNP and hs-TnT levels in the 
large, community-based Atherosclerosis Risk in Communities (ARIC) Study.
 METHODS
 Study population
The overall ARIC Study is an ongoing, prospective observational study. Detailed study 
rationale, design, and procedures have been previously published (16). The original cohort 
included 15,792 participants aged 45 to 64 years recruited between 1987 and 1989 (Visit 1), 
selected from 4 communities in the United States. The investigation conforms with the 
principles outlined in the Declaration of Helsinki. Institutional review boards from each site 
approved the study, and informed consent was obtained from all participants. In this study 
we considered the 11,656 participants attending Visit 4 (1996–1998). We excluded those 
with prevalent CAD or HF (n=1,429) and participants whose race was neither black nor 
white, or with missing NT-ProBNP, hs-TnT or smoking data, resulting in 9,649 individuals 
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eligible for cross-sectional analysis. In addition, we analyzed follow-up data from Visit 4 to 
Visit 5 (2011–2013). Among the 9,649 participants initially included, 2,043 died during 
follow-up and 1,151 were excluded because of incident CAD or HF between Visits 4 and 5. 
Furthermore, participants who did not attend Visit 5 or with missing NT-ProBNP, hs-TnT 
and smoking data at Visit 5 were excluded. Because we wanted to assess the impact of 
chronic obstructive pulmonary disease (COPD) as a covariate, participants with missing 
spirometry at Visit 5 were also excluded, resulting in 3,151 participants for longitudinal 
analysis (Supplemental Figure 1).
 Measurements
 Smoking history—Smoking history was ascertained by means of an interviewer-
administered questionnaire. Participants were asked if they currently smoked cigarettes or 
whether they had done so in the past. Participants who stated that they never smoked but 
referred exposure to environmental tobacco smoke for more than 1 hour per week were 
classified as passive smokers (17). This approach yielded 4 categories at Visit 4: never 
smokers, passive smokers, former smokers and current smokers. Smoking pack-years 
(number of packs per day multiplied by years of smoking) were calculated among current 
and former smokers at Visit 4. At Visit 5, participants were classified as current, former and 
never smokers and information about pack-years and exposure to environmental tobacco 
smoke was not available.
 Cardiac Biomarkers—Blood samples were taken at ARIC Visits 4 and 5 and plasma 
was stored centrally at −80°C. Hs-TnT was measured using a highly sensitive assay (Elecsys 
Troponin T; Roche Diagnostics, Indianapolis, IN) with a limit of detection of 5 ng/L (18). 
NT-ProBNP was measured using electrochemiluminescent immunoassay (Roche 
Diagnostics) with a lower detection limit of 5 pg/mL (8). Participants with NT-ProBNP and 
hs-TnT levels below the lower limits of detection were assigned values equal to half of the 
lower limits of detection (8). The variability in NT-proBNP and hsTnT concentrations 
related to frozen storage and freeze–thaw cycles and the reliability coefficient and interassay 
coefficient of variation for both biomarkers have been described previously (8).
 Measurement of Other Covariates and Outcomes—Information on 
demographics, clinical history, anthropometric measures, blood pressure, heart rate and lipid 
levels was obtained at Visits 4 and 5. Definitions for hypertension, diabetes mellitus, current 
alcohol drinking, CAD and HF were used as previously described in the ARIC study (19). 
At Visit 4, COPD was defined as a self-report of physician diagnosis of either emphysema or 
chronic bronchitis. At Visit 5, spirometry was performed and subjects with forced expiratory 
volume in 1 second/forced vital capacity ratio <0.65 were considered to have COPD (20).
From Visit 4 to December 2012, we assessed the incidence of death, non-fatal CAD, defined 
as myocardial infarction or coronary revascularization, and non-fatal HF, defined by HF 
hospitalization (19). Deaths were determined through linkage with the National Death Index.
 Statistical methods—Descriptive data are presented as the mean ± standard deviation 
for normally distributed variables and median [25th–75th percentile] for non-normally 
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distributed variables. Log-transformed variables are also described using geometric mean 
(95% confidence intervals). Significant pairwise comparisons are shown only for variables 
in which a significant global difference was detected using one-way ANOVA or Kruskal-
Wallis tests. Categorical variables are expressed as proportions and were compared by the 
chi-square test.
For cross-sectional analyses, NT-ProBNP was modeled continuously using the log 
transformed value to achieve normality and categorically using a threshold of 125 pg/mL as 
previously described (21). Hs-TnT was heavily skewed and was modeled as a categorical 
variable using a threshold of 14 ng/L as formerly reported (13, 18, 22). To assess the 
association between smoking status and cardiac biomarkers in cross-sectional analysis we 
used multivariable linear models for NT-ProBNP and logistic models for elevated NT-
ProBNP and hs-TnT.
For longitudinal analyses, we calculated the change in NT-ProBNP and hs-TnT values at 
follow-up (Visit 5), compared to baseline (Visit 4) as the difference on the log scale. The 
relationship between Visit 4 smoking status and change in cardiac biomarkers was analyzed 
by linear regression analysis. To illustrate the magnitude of change in cardiac biomarkers, 
values of adjusted geometric means of NT-ProBNP and hs-TnT at Visits 4 and 5 were 
presented. The association between Visit 4 smoking status and the incidence of elevated NT-
ProBNP or hs-TnT at Visit 5 was assessed by logistic regression analysis, excluding subjects 
with elevated NT-ProBNP or hs-TnT levels at Visit 4.
To evaluate the smoking-biomarker relationship, we used additive multivariable models. 
Model covariates were selected based on a priori knowledge. Three regression models were 
constructed: Model 1 included age and gender; Model 2 additionally adjusted for race, field 
center, diabetes mellitus, hypertension, body mass index, current alcohol drinking, systolic 
blood pressure, heart rate, estimated glomerular filtration rate and COPD at Visit 4; Model 3: 
additionally adjusted for diabetes mellitus, hypertension, body mass index, current alcohol 
drinking, systolic blood pressure, heart rate, estimated glomerular filtration rate, smoking 
status and COPD at Visit 5. In cross-sectional analysis, Models 1 and 2 were used, while in 
longitudinal analysis, all three models were used and the baseline (Visit 4) values of the 
corresponding outcome variable (NT-ProBNP or hs-TnT) being modeled were also included. 
The cross-sectional associations between pack-years of smoking and elevated NT-ProBNP 
and hs-TnT at Visit 4 were assessed in ever smokers using logistic regression analysis 
adjusted for covariates included in Model 2. To adjust for possible bias due to selective 
attrition between Visits 4 and 5, we performed a sensitivity analysis incorporating estimated 
inverse probability weights based on the likelihood that a given patient at Visit 4 would 
return and have available biomarkers at Visit 5. The likelihood ratio test was used to assess 
gender and race-based interactions between cardiac biomarkers and smoking categories.
To evaluate the relationship between smoking status, elevated levels of biomarkers and 
incident HF, CAD or death from Visit 4 to December 2012, we calculated the rate of events 
per 100 person-years at risk and estimated hazard ratios, based on univariate Cox regression 
analysis. We also investigated the potential impact of smoking-related competing risk of 
death on the relationship between smoking status at Visit 4 and incident elevated hs-TnT at 
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Visit 5, by performing sensitivity analyses including participants without elevated hs-TnT at 
Visit 4, first creating a composite outcome of death or elevated hs-TnT at Visit 5, and also 
creating an ordinal outcome denoting Visit 5 status as 1) alive without elevated hs-TnT; 2) 
alive with elevated hs-TnT; and 3) died prior to Visit 5.
Two-sided p values <0.05 were considered significant. Analyses were performed using Stata 
version 13.1 (Stata Corp., College Station, Texas).
 RESULTS
 Sample characteristics
Among the 9,649 participants included from Visit 4, never smokers were more likely to be 
women than the other smoking groups (Table 1). Current smokers were younger, had lower 
mean blood pressure and body mass index, were more likely to be current alcohol drinkers, 
had higher heart rate and glomerular filtration rate and higher prevalence of hypertension 
and COPD than never smokers. When compared to never smokers, passive smokers were 
younger, had higher body mass index and higher prevalence of diabetes, while former 
smokers were more frequently black, diabetic and alcohol drinkers, had higher prevalence of 
COPD and had lower heart rate.
 Cross-sectional analysis of smoking and cardiac biomarkers
Current smokers showed higher levels of NT-ProBNP compared to never smokers in 
multivariable analysis (Table 2). In addition, current smokers and to a minor extent former 
smokers had a higher prevalence of elevated NT–ProBNP in comparison with never 
smokers. Although we did not find a significant difference in hs-TnT among the smoking 
groups (Table 2), when using a more comprehensive measure of smoking based on 
cumulative intensity and duration assessed by pack-years, greater smoking was significantly 
associated with elevated NT-ProBNP (p<0.001) and hs-TnT (p=0.01) among ever smokers 
(Figure 1). Since smoking and elevated troponin levels are reported to be associated with 
higher death rates (22), we hypothesized that survival bias might have influenced our ability 
to detect differences in hs-TnT among the smoking groups. In accordance with this 
hypothesis, we found that current smokers with elevated hs-TnT at Visit 4 had the highest 
rate of death among the studied subgroups (Table 3). Furthermore, the combination of 
current smoking and elevated hs-TnT was also associated with the highest rate of non-fatal 
HF and CAD among the studied population (Table 3).
 Longitudinal analysis of smoking and cardiac biomarkers
Subjects included in the follow-up analysis (n=3,151) had similar baseline (Visit 4) clinical 
characteristics compared to those of the full sample (Supplemental Table 1). The majority of 
never, passive and former smokers at Visit 4 did not smoke at follow-up (Visit 5), while only 
36% of current smokers at Visit 4 were smoking at Visit 5 (Supplemental Table 2). We found 
that current and former smokers had higher increases in NT-ProBNP levels and higher risk 
of developing elevated NT-ProBNP at follow-up than never smokers (Table 4). In 
comparison with never smokers, current smokers and to a marginal degree former smokers 
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at Visit 4 demonstrated higher long-term increases in hs-TnT levels and a higher risk of 
developing elevated hs-TnT at Visit 5 (Table 4).
We hypothesized that our initial analysis of the association between smoking status at Visit 4 
and incident elevated hs-TnT at Visit 5 was likely to underestimate the true relationship due 
to smoking-related competing risk of death between Visits 4 and 5. In order to address this, 
we performed sensitivity analyses including participants without elevated hs-TnT at Visit 4, 
first creating a composite outcome of death or elevated hs-TnT at Visit 5, and also creating 
an ordinal outcome denoting Visit 5 status as 1) alive without elevated hs-TnT; 2) alive with 
elevated hs-TnT; and 3) died prior to Visit 5 (Figure 2 and Supplemental Table 3). These 
analyses showed that current smoking at Visit 4 was strongly related to the composite 
outcome of death or elevated hs-TnT at Visit 5 and to Visit 5 status, suggesting that it may 
be difficult to observe smokers with elevated hs-TnT because of the very high likelihood of 
death.
To adjust for possible bias due to selective attrition between Visits 4 and 5, we applied 
calculated inverse probability weights to the multivariable models (Supplemental Table 4). 
However, this approach did not change the associations between smoking and long-term 
change in cardiac biomarkers. Furthermore, there was no significant interaction by gender or 
race for the relationship between smoking and NT-ProBNP or hs-TnT in cross-sectional and 
longitudinal analyses.
 DISCUSSION
In a large community-based cohort free of CAD and HF, cumulative cigarette exposure, 
assessed by pack-years of smoking, was associated with higher NT-ProBNP and hs-TnT 
levels among ever smokers. Furthermore, participants who were current smokers at Visit 4 
had greater changes in NT-ProBNP and hs-TnT after 15 years of follow-up, even adjusting 
for Visit 4 and Visit 5 covariates. Conversely, former smokers had minor long-term changes 
in NT-ProBNP and hs-TnT in comparison with never smokers.
Previous cross-sectional studies showed conflicting results regarding the relationship 
between smoking status and NT-ProBNP (9, 10, 11), while the few available studies with 
longitudinal design did not report an association between smoking and long-term changes in 
this biomarker in general populations (15, 23). We found that a history of active smoking 
was associated with higher NT-ProBNP and long-term changes in this biomarker. Moreover, 
NT-ProBNP levels were directly related to number of pack-years of smoking, suggesting 
that myocardial wall stress may be related to overall smoking burden. Our larger sample size 
and longer period of follow-up might have increased the ability to detect significant 
associations, thus explaining the differences between our findings and those of previous 
reports (9, 10, 11, 15).
Our data also showed that heavier cumulative cigarette exposure was associated with a 
higher likelihood of elevated hs-TnT levels among ever smokers, suggesting that subclinical 
myocardial injury is directly related to the intensity and duration of cigarette exposure. 
Conversely, we detected no association between smoking status and hs-TnT in cross-
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sectional analysis. One possible explanation for this latter finding would be survival bias. 
Given that smoking and elevated troponin levels are associated with higher death rates (22), 
it can be argued that smokers with elevated hs-TnT were more likely to die prior the cross-
sectional visit. In accordance with this assumption, we observed that participants who where 
current smokers with high hs-TnT at Visit 4 had the highest death rate among all studied 
participants. Although we were not able to assess whether active smoking coupled with high 
hs-TnT was associated with higher death rate prior to Visit 4, these results suggest that 
survival bias might have influenced our ability to detect differences in hs-TnT among the 
smoking groups. In addition, we showed that current smoking at Visit 4 was associated with 
greater changes in hs-TnT levels and higher incidence of elevated hs-TnT after 15 years of 
follow-up. These data support the notion that tobacco might be a risk factor for long-term 
subclinical myocardial injury.
Prior data from the ARIC cohort and the Health, Aging, and Body Composition Study 
showed that current smokers and to a minor extent former smokers had higher risk of 
incident HF, independent of coronary artery events (2, 3). However, the pathophysiological 
pathways that mediate the long-term deleterious effects of smoking on the myocardium are 
far from being established. In the present study we shed light on this issue by showing that 
current and former smoking were independent predictors of soluble biomarkers reflecting 
increased ventricular wall stress and subclinical myocardial injury after 15 years of follow-
up. Furthermore, we observed that the magnitude of long-term association with NT-ProBNP 
and hs-TnT was stronger in current than in former smokers. Given that these biomarkers are 
surrogates and predictors of cardiac dysfunction (7, 8, 15), our findings are consistent with 
the results of epidemiological studies that showed that current smoking was associated with 
HF to a greater extent than prior smoking (2, 3). It was also noteworthy that among our 
participants who were current and former smokers at Visit 4, the majority of them were not 
smoking at Visit 5. This observation indicates that tobacco-associated myocardial alterations 
may persist even after smoking cessation.
Several mechanisms may be proposed to explain the association between smoking and 
higher NT-ProBNP and hs-TnT. Smoking could increase these biomarkers by leading to 
higher blood pressure levels (24, 25) and COPD (26, 27). However, we did not detect 
elevated blood pressure levels in subjects with a history of smoking. Furthermore, the 
relationship between smoking and cardiac biomarkers persisted after adjustment for blood 
pressure levels and COPD, indicating that these factors did not explain our findings. 
Smoking-induced CAD could also provide an alternative explanation for our results (28). In 
contrast to this hypothesis, subjects with overt CAD were excluded from the analysis. 
However, we cannot discard that subclinical myocardial ischemia, especially as a 
consequence of smoking-induced coronary microvascular dysfunction (29), contributed to 
justify our findings. Lastly, it is possible that the rise in biomarkers was a consequence of 
direct effects of tobacco on the myocardium. This hypothesis is supported by experimental 
evidence showing that tobacco smoke may lead to myocardial damage, by inducing 
hypoxemia, oxidative stress and activation of matrix-metalloproteinases (4). Nevertheless, 
further studies are necessary to unveil the precise mechanisms by which smoking influences 
NT-ProBNP and hs-TnT levels.
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A number of limitations should be noted. This is an observational study and cigarette 
smoking data were self reported in a questionnaire administered by an interviewer, thus 
participants may have underreported their smoking habits. Data regarding passive smoking 
were limited to one time point (Visit 4), therefore we could not assess the role of exposure to 
second-hand smoking before and after Visit 4 in our analyses. Although additive 
multivariable models were used, residual confounding cannot be excluded. Furthermore, it is 
possible that smoking-related selective attrition before Visit 5 introduced biased estimates in 
our longitudinal analysis. However, our results did not substantially change after applying 
inverse-probability-of-attrition weights to our multivariable analyses. Lastly, NT-ProBNP 
and hs-TnT were measured from frozen samples and were therefore subject to potential 
degradation as with any stored sample. Nevertheless, this approach has been standard 
practice in epidemiological studies. The strengths of this study include its large size, the 
long period of follow-up and the ability to adjust for cardiovascular risk factors and 
demographic factors. Moreover, because smoking is associated with CAD and HF, which 
may in turn lead to changes in NT-ProBNP and hs-TnT, we excluded participants with 
prevalent CAD or HF in order to focus on biomarker changes not induced through these 
pathways.
 CONCLUSIONS
This study showed that cumulative cigarette exposure was associated with elevated NT-
ProBNP and hs-TnT levels in a large community population without overt CAD and HF. 
Furthermore, current smoking and to a lesser extent former smoking predicted a 15-year 
progression of NT-ProBNP and hs-TnT. These findings suggest that cigarette smoking might 
be harmful to the heart beyond stimulating CAD, potentially by increasing ventricular wall 
stress and inducing subclinical myocardial injury.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Cross-sectional association between smoking intensity and duration and cardiac biomarkers. 
Logistic regression analysis of elevated N-terminal Pro–B-type natriuretic peptide (NT-
ProBNP) (≥125 pg/mL) and elevated high sensitivity Troponin T (hs-TnT) (≥14 ng/L), as a 
function of pack-years of smoking among ever smokers at Visit 4. The 95% confidence 
intervals are indicated by the dash lines. Models are adjusted for age, gender, race, body 
mass index, field center, diabetes mellitus, hypertension, current alcohol drinking, systolic 
blood pressure, heart rate, chronic obstructive pulmonary disease and estimated glomerular 
filtration rate.
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Stacked bar plot regarding the relationship between smoking status at baseline (Visit 4) and 
hs-TnT status (normal or elevated) or death at Visit 5. Normal and elevated hs-TnT values 
were considered as values <14 ng/L and ≥14 ng/L, respectively. In these analyses, 
participants with hs-TnT ≥14 ng/L at Visit 4 (n=441) were excluded. hs-TnT – high-
sensitivity Troponin T.
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Table 1









Male gender (n, %) 795 (27) 553 (35)* 2,077 (56)* 627 (45)*
Age (years) 62.9 ± 5.7 62.0 ± 5.5* 63.1 ± 5.7 61.5 ± 5.5*
Black (n,%) 650 (22) 381 (24) 646 (17)* 347 (25)
Body mass index (kg/m2) 28.7 ± 5.6 29.5 ± 5.7* 28.8 ± 5.2 26.7 ± 5.1*
Pack-years of smoking ---- ---- 17 [7, 32] 37 [23, 49]
Systolic blood pressure (mmHg) 128 ± 19 128 ± 19 127 ± 18 125 ± 20*
Diastolic blood pressure (mmHg) 71 ± 10 72 ± 10 72 ± 10 69 ± 11*
Hypertension (n,%) 1337 (46) 730 (46) 1642 (44) 552 (39)*
Heart rate (b.p.m.) 63 ± 10 63 ± 10 62 ± 10* 65 ± 11*
Diabetes mellitus (n,%) 391 (13) 250 (16)* 590 (16)* 175 (12)
Current alcohol drinkers (n,%) 1186 (41) 687 (43) 2229 (60)* 802 (57)*
COPD (n, %) 148 (5) 81 (5) 312 (8)* 181 (13)*
LDL-cholesterol (mg/dL) 124 ± 33 125 ± 35 123 ± 32 124 ± 35
HDL-cholesterol (mg/dL) 53 ± 17 52 ± 17* 49 ± 17* 49 ± 17*
eGFR (mL/min/1.73m2) 86 ± 16 87 ± 16 86 ± 15 91 ± 16*
NT-ProBNP (pg/mL) 67 [35, 122] 60 [30, 113]* 62 [29, 119]* 66 [33, 133]
  Geometric Mean (pg/mL) 62 (60–65) 56 (53–59)* 56 (54–59)* 63 (60–68)
  Elevated NT-ProBNP (n, %)† 700 (24) 335 (21)* 878 (24) 373 (27)
Hs-TnT (ng/L) <5 [<5, 7] <5 [<5, 7] 5 [<5, 8]* <5 [<5, 6]*
  Elevated Hs-TnT (n, %)‡ 179 (6) 108 (7) 327 (9)* 79 (6)
*
p<0.05 compared to never smokers.
†
Elevated NT-ProBNP was defined as values ≥ 125 pg/mL
‡
Elevated hs-TnT was defined as values ≥ 14 ng/L
Normal-distributed continuous variables are presented as mean ± standard deviation. NT-ProBNP values are presented as median [25th–75th 
percentile] and geometric mean (95% confidence interval); Pack-years and hs-TnT values are shown as median [25th–75th percentile].
COPD – chronic obstructive pulmonary disease; eGFR - estimated glomerular filtration rate; HDL – high-density lipoprotein; Hs-TnT - high-
sensitivity troponin T; LDL – low-density lipoprotein; NT-ProBNP - N-terminal pro–B-type natriuretic peptide.
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Table 2
Cross-sectional associations between cardiac biomarkers and smoking status at Visit 4
Model 1 p‡ Model 2 p‡




Never Smokers 56 (54, 58) Ref 55 (53, 58) Ref
Passive Smokers 56 (53, 59) 0.78 56 (54, 59) 0.55
Former Smokers 59 (57, 62) 0.027 58 (56, 60) 0.07
Current Smokers 69 (65, 73) <0.001 73 (69, 77) <0.001




Never Smokers 22 (20, 23) Ref 21 (20, 23) Ref
Passive Smokers 21 (19, 23) 0.63 21 (19, 23) 0.98
Former Smokers 25 (23, 26) 0.002 24 (23, 26) 0.003
Current Smokers 29 (27, 31) <0.001 30 (28, 33) <0.001




Never Smokers 8 (7, 9) Ref 8 (7, 9) Ref
Passive Smokers 8 (7, 9) 0.63 8 (7, 9) 0.87
Former Smokers 7 (6, 8) 0.38 7 (6, 8) 0.31
Current Smokers 6 (5, 7) 0.06 6 (5, 7) 0.24
*
Results reporting adjusted geometric means and 95% confidence intervals (CI) of NT-ProBNP at Visit 4 obtained from linear regression analysis.
†
Results reporting the adjusted proportions and 95% CI of elevated NT-ProBNP or hs-TnT at Visit 4 obtained from logistic regression analysis.
‡
p-values regarding the differences in adjusted geometric means or adjusted proportions between never smokers, as the reference (Ref), and the 
other smoking groups.
hs-TnT – high-sensitivity Troponin T; NT-ProBNP - N-terminal pro–B-type natriuretic peptide.
Model 1: Adjusted for age and gender
Model 2: Further adjusted for race, body mass index, field center, diabetes mellitus, hypertension, chronic obstructive pulmonary disease, current 
alcohol drinking, systolic blood pressure, heart rate and estimated glomerular filtration rate.
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